Research programme: IgA antibody anticancer therapeutics - B Cell Design
Latest Information Update: 08 Aug 2016
At a glance
- Originator B Cell Design
- Class Immunoglobulin isotypes; Monoclonal antibodies
- Mechanism of Action Carcinoembryonic antigen inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Colorectal cancer
Most Recent Events
- 05 Aug 2016 Investigation in Colorectal cancer in France (unspecified route)